Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 8;6(5):1420-1431.
doi: 10.1182/bloodadvances.2021006208.

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas

Min Jung Koh  1 , Mwanasha H Merrill  2 , Min Ji Koh  3 , Robert Stuver  4 , Carolyn D Alonso  5   6 , Francine M Foss  7 , Angel M Mayor  8 , John Gill  9 , Marta Epeldegui  10 , Edward Cachay  11 , Jennifer E Thorne  12 , Michael J Silverberg  13 , Michael A Horberg  14 , Keri N Althoff  15 , Ank E Nijhawan  16 , Kathleen A McGinnis  17 , Jennifer S Lee  15 , Charles S Rabkin  18 , Sonia Napravnik  19 , Jun Li  20 , Jessica L Castilho  21 , Changyu Shen  5   22   6 , Salvia Jain  5   23   6
Affiliations

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas

Min Jung Koh et al. Blood Adv. .

Erratum in

Abstract

There are no studies comparing the prognosis for mature T-cell lymphoma (TCL) in people with HIV (PWH) to people without HIV (PWoH) and to AIDS-defining B-cell lymphomas (A-BCLs) in the modern antiretroviral therapy era. North American AIDS Cohort Collaboration on Research and Design and Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment are cohorts that enroll patients diagnosed with HIV and TCL, respectively. In our study, 52, 64, 101, 500, and 246 PWH with histologic confirmation of TCL, primary central nervous system lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and Hodgkin's lymphoma (HL), respectively, and 450 TCLs without HIV were eligible for analysis. At the time of TCL diagnosis, anaplastic large-cell lymphoma (ALCL) was the most common TCL subtype within PWH. Although PWH with TCL diagnosed between 1996 and 2009 experienced a low 5-year survival probability at 0.23 (95% confidence interval [CI]: 0.13, 0.41), we observed a marked improvement in their survival when diagnosed between 2010 and 2016 (0.69; 95% CI: 0.48, 1; P = .04) in contrast to TCLs among PWoH (0.45; 95% CI: 0.41, 0.51; P = .53). Similarly, PWH with ALCLs diagnosed between 1996 and 2009 were associated with a conspicuously inferior 5-year survival probability (0.17; 95% CI: 0.07, 0.42) and consistently lagged behind A-BCL subtypes such as Burkitt's (0.43; 95% CI:0.33, 0.57; P = .09) and DLBCL (0.17; 95% CI: 0.06, 0.46; P = .11) and behind HL (0.57; 95% CI: 0.50, 0.65; P < .0001). Despite a small number, those diagnosed between 2010 and 2016 experienced a remarkable improvement in survival (0.67; 95% CI: 0.3, 1) in comparison with PWoH (0.76; 95% CI: 0.66, 0.87; P = .58). Thus, our analysis confirms improved overall survival for aggressive B- and T-cell malignancies among PWH in the last decade.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS at 5 years for patients with TCL and NK/TCL enrolled in COMPLETE relative to people with HIV with TCL and NK/TCL and A-BCL enrolled in NA-ACCORD. Kaplan-Meier analysis of (A) OS for all mature patients with TCL and NK/TCL with and without HIV, (B) OS for all patients with ALCL with and without HIV, (C) OS for all patients with TCL and NK/TCL stratified by CD4 cell count in cells/µL and viral load in copies/mL, and (D) OS for all mature patients with TCL and NK/TCL and A-BCLs stratified by subtype.
Figure 2.
Figure 2.
OS at 5 years for people with HIV diagnosed with A-BCL and TCL and NK/TCL in NA-ACCORD per calendar period. Kaplan-Meier analysis of (A) OS for patients with TCL and NK/TCL stratified by period of diagnosis from 1996 to 2016, (B) OS of PWH with A-BCL such as BL, PCNSL, DLBCL, and HL diagnosed from 1996 to 1999, (C) OS of PWH A-BCL such as BL, PCNSL, DLBCL, and HL diagnosed from 2000 to 2009, and (D) OS of PWH with A-BCL such as Burkitt’s lymphoma, PCNSL, DLBCL, and HL diagnosed from 2010 to 2016.
Figure 3.
Figure 3.
OS at 5 years for patients with TCL and NK/TCL enrolled in COMPLETE relative to people with HIV with TCL and NK/TCL enrolled in NA-ACCORD between 2010 and 2016. Kaplan-Meier analysis of (A) OS for all mature patients with TCL and NK/TCL with and without HIV, (B) OS for all patients with ALCL with and without HIV.
See this image and copyright information in PMC

References

    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. - PubMed
    1. Hsi ED, Horwitz SM, Carson KR, et al. . Analysis of peripheral T-cell lymphoma diagnostic workup in the United States. Clin Lymphoma Myeloma Leuk. 2017;17(4):193-200. - PubMed
    1. Vose JM. Peripheral T-cell non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am. 2008;22(5):997-1005, x. - PubMed
    1. Lansigan F, Horwitz SM, Pinter-Brown LC, et al. . Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry. Acta Haematol. 2020;143(1):40-50. - PubMed
    1. Coiffier B, Federico M, Caballero D, et al. . Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev. 2014;40(9):1080-1088. - PubMed

Publication types

MeSH terms

Grants and funding